AFP and gastric cancer: Besides, a study in gastric cancer showed that the median OS and progression-free survival in patients whose AFP level decreased by ≥ 50% were respectively 32.0 (4–74) and 24.0 (1–66) months, and which in patients whose AFP level decreased by < 50% were respectively 12.5 (0–69) and 9.0 (0–63) months [28].